InfuSystem Holdings, Inc.

$ 9.42 7.66 %

InfuSystem Holdings, Inc. delivers infusion pumps, along with associated products and support services, to clients across the United States and Canada. The enterprise operates through two principal divisions: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The ITS segment specializes in providing electronic ambulatory infusion devices and accompanying disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy facilities. These devices are crucial for managing various cancers, including colorectal cancer, as well as for pain management and other therapeutic needs. Moreover, the company markets, leases, and rents out a selection of new and pre-owned infusion pumps (both pole-mounted and ambulatory) and other vital durable medical equipment. It also sells consumables essential for treatment. InfuSystem further extends its offerings to include biomedical recertification, maintenance, and repair services for oncology practices and diverse alternative care settings, such as home care and home infusion providers, skilled nursing facilities, pain centers, and hospitals. Additionally, InfuSystem furnishes both local and field-based customer assistance and manages dedicated pump service and repair facilities. The company was founded in 2005 and maintains its corporate headquarters in Rochester Hills, Michigan.

CEO: Carrie A. Lachance - https://www.infusystem.com

Price objectif

$15 59.24 %

Recommandation

Buy

DCF

$ 7.86

Loading data...

INFU vs S&P500

Loading data...

No data available.

Quick ratio

1.80

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

25.46

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

0.37

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

14.00 %

reflects reasonable profitability, showing good use of equity.

ROIC

10.61 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

11.09

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.39

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

1.00

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
8 indicates good financial health
Altman score
4.10 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.12 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.23 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.